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ABSTRACT 
α-Carboxy nucleoside phosphonates (α-CNPs) are modified nucleotides that represent a novel class of 
nucleotide-competing reverse transcriptase (RT) inhibitors (NcRTIs). They were designed to act directly 
against HIV-1 RT without the need for prior activation (phosphorylation). In this respect, they differ from 
the nucleoside or nucleotide RTIs [N(t)RTIs] that require conversion to their triphosphate forms before 
being inhibitory to HIV-1 RT. The guanine derivative (G-α-CNP) has now been synthesized and 
investigated for the first time. The (L)-(+)-enantiomer of G-α-CNP directly and competitively inhibits HIV-
1 RT by interacting with the substrate active site of the enzyme. The (D)-(-)-enantiomer proved inactive 
against HIV-1 RT. In contrast, the (+)- and (-)-enantiomers of G-α-CNP inhibited herpes (i.e. HSV-1, 
HCMV) DNA polymerases in a non- or uncompetitive manner, strongly indicating interaction of the (L)-
(+)- and the (D)-(-)-G-α-CNPs at a location different from the polymerase substrate active site of the 
herpes enzymes. Such entirely different inhibition profile of viral polymerases is unprecedented for a 
single antiviral drug molecule. Moreover, within the class of α-CNPs, subtle differences in their sensitivity 
to mutant HIV-1 RT enzymes were observed depending on the nature of the nucleobase in the α-CNP 
molecules. The unique properties of the  -CNPs make this class of compounds, including G-α-CNP, direct 
acting inhibitors of multiple viral DNA polymerases. 
 
Keywords: nucleoside/nucleotide analogs, nucleotide competing RT inhibitor, α-carboxy nucleoside 
phosphonates, HIV reverse transcriptase, herpes DNA polymerase 
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1. Introduction 
A broad variety of antiviral drugs are clinically approved (for an overview, see ref. 1). The 
majority of these drugs are nucleoside analogues for which the virus-encoded DNA and RNA polymerases 
are the prime targets for the inhibition of virus replication. Indeed, a variety of nucleoside analogues 
efficiently inhibit the herpes DNA polymerases encoded by herpes simplex virus type 1 and type 2 (2), 
varicella zoster virus (VZV) (2, 3) and human cytomegalovirus (HCMV) (2, 4), the reverse transcriptase of 
retroviruses such as HIV-1 and HIV-2 (5), the DNA polymerase of hepatitis B virus (6), as well as the RNA 
polymerases specified by several RNA viruses such as respiratory syncytial virus (7), influenza viruses (8), 
and also flaviruses as exemplified by hepatitis C virus (9, 10). Such inhibitors need to be activated 
(phosphorylated) by virus-encoded kinases or by cellular nucleoside/nucleotide kinases to their 5’-
triphosphate derivatives, or in case of the acyclic nucleoside phosphonates to their diphosphate 
derivatives before these nucleoside/nucleotide analogues can be recognized by the viral DNA or RNA 
polymerases (1-10). The nucleoside analogues are often incorporated in the growing viral DNA or RNA 
chain, and function as chain terminators (2, 5). Instead, several non-nucleoside derivatives have also 
been discovered to act against viral polymerases, either at a non-substrate active site of the enzyme 
[such as the non-nucleoside RT inhibitor (NNRTI) interaction with HIV-1 RT] (11-13) or at the substrate-
active site of the RT enzyme [such as the nucleotide-competing RT inhibitor (NcRTI) (i.e. INDOPY)] (14-
16). Such agents differ from a classic nucleoside structure and do not need prior metabolic conversion to 
exhibit inhibitory activity against their specific polymerase target(s).  
 Members of the nucleoside analogue class of compounds represent the highest number of 
clinically approved antiviral drugs (1). However, due to their obligatory dependence on cellular 
metabolism and often inefficient intracellular conversion to their antivirally-active phosphorylated 
metabolites, efforts have been devoted to deliver directly and more efficiently the nucleoside/nucleotide 
drugs intracellularly as their activated (mono)phosphorylated derivatives (17-20). Although this approach 
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proved successful in several cases, the compounds usually still need to be converted to their eventual 
triphosphate equivalent before being inhibitory against the viral polymerase. 
 Recently, we have reported an entirely different approach to design nucleotide analogues (Fig. 1) 
that are directly inhibitory to viral DNA polymerases without the need of additional metabolic 
conversions (21, 22). The prototype of these novel nucleotide analogues consists of a nucleobase, 
connected to an α-carboxy phosphonate moiety through a cyclic cyclopentyl linker entity. 
Crystallographic, kinetic and biochemical studies have shown that such compounds could directly bind to 
the substrate-active site of HIV-1 RT without any prior metabolic conversion enabling base pairing and 
active site Mg2+  ion chelation similar to the natural dNTPs (21, 23). It was shown that one oxygen of the 
carboxylate and two oxygens of the phosphonate part of the α-CNP backbone are involved in Mg2+ ion 
coordination. These three oxygens mimic the three chelating  and phosphate oxygen atoms of 
a dNTP (21, 23).  
Although the thymine-, uracil-, cytosine- and adenine-α-CNPs are potent inhibitors of HIV RT, 
they are less inhibitory to herpes DNA polymerases (21). However, the guanine α-CNP derivative had not 
been synthesized and evaluated in previous studies. Given the importance of guanine nucleoside 
analogues as antiherpes (i.e. acyclovir, ganciclovir) or anti-HIV (i.e. abacavir) agents, we now synthesized 
the guanine α-CNP (G-α-CNP) and investigated its inhibitory activity against HIV-1 RT and herpes DNA 
polymerases. The G-α-CNP derivative displayed comparable inhibitory activity against HIV-1 RT and the 
herpes DNA polymerases as the prototype thymine-α-CNP, but showed differences in its inhibitory 
activity against mutant HIV-1 reverse transcriptases. Its mechanism of action appears to be significantly 
different for HIV-1 versus the herpes DNA polymerases. This novel compound is of interest as a potential 
dually-active compound with significant concomitant anti-HIV and anti-herpes virus DNA polymerase 
activity. 
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2. Materials and methods 
2.1. Compound synthesis and characterization data 
G-α-CNP [cis-9-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}guanine] 
Racemic G-α-CNP was prepared in nine steps starting from 2-cyclopentenone. The materials were 
purchased from Acros Organic, Fisher Scientific Ireland Ltd. (Dublin, Ireland). The enantiomers (L)-(+)-G-
α-CNP and (D)-(−)-G-α-CNP were prepared in seven steps starting from (1R,4S)-(−)-cis-4-acetoxy-2-
cyclopenten-1-ol and (1S,4R)-(+)-cis-4-acetoxy-2-cyclopenten-1-ol, respectively. Full details of the 
synthesis will be described elsewhere. Characterization data: 1H NMR (400 MHz, D2O): δ 1.08–2.00 (4H, 
m), 2.00–2.14 (1H, m), 1H 2.40–2.50 (1H, m), 3.93 (0.5H, d, J = 18.2), 3.99 (0.5H, d, J = 18.3) 4.03–4.10 
(1H, m), 4.51-4.62 (1H, m), 8.03 (0.5H, s), 8.04 (0.5H, s); 13C NMR (125 MHz, D2O): δ 9.4, 30.5, 30.6, 37.8, 
38.8, 53.3, 53.5, 80.0, 80.5, 115.8, 138.8, 151.2, 153.4, 158.8, 158.9, 177.6; 31P NMR (162 MHz, D2O): δ 
12.36, 12.48; m/z (ES−) 372.1 [M−H]-; HRMS (ES+) Exact mass calculated for C12H17N5O7P [M+H]
+ 
374.0866; found 374.0861. 
2.2. Reverse transcriptase, nucleic acids, and small molecules 
HIV-1 reverse transcriptase was expressed and purified as described previously (33). 
Oligodeoxynucleotides were synthesized and purchased from Integrated DNA Technologies, Coralville, 
USA. The following sequences were used as templates: PBS36a, 
GTAACTAGATATCCCTCAGACCCTTTTAGTCAGAAT; PBS36t, 
GTAACTAGAAATCCCTCAGACCCTTTTAGTCAGAAT, PBS36c, 
GTAACTAGAGATCCCTCAGACCCTTTTAGTCAGAAT; PBS36g, 
GTAACTAGACATCCCTCAGACCCTTTTAGTCAGAAT; PPT57, CGTTGGGAGTGAATTAGCC-
CTTCCAGTCCCCCCTTTTCTTTTAAAAAGTGGCTAAGA. Primer sequences used were: PPT-17, 
GCCACTTTTTAAAAGAAAAGGGGGG; , GAGTGGTATAGTGGAGTGAA; 8a, 
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TTCTGACTAAAAGGGTCTGAGGGAT; PPT+16, AAAGGGGGGACTGGAAGGGCTAATT. Deoxynucleotides were 
purchased from Integrated DNA Technologies. 
2.3. DNA synthesis 
A 3-fold excess of PPT-57 DNA template was heat-annealed to 50 nM 5'-fluorolabeled PPT-17 primer, 
then incubated with 250 nM of RT in a buffer containing 50 mM Tris-HCl (Sigma, St. Louis, MO), pH 7.8, 
50 mM NaCl (Sigma), 0.3 mM EDTA (Sigma), and 0.5 µM of each of dATP, dTTP, dGTP, and dCTP (GE 
Healthcare, Pittsburgh, PA) (33). The samples were preincubated at 37°C for 5 minutes before starting 
the reactions. For inhibitor dose-response experiments, each of the four inhibitors was titrated up to 100 
µM, and the reaction was initiated with 6 mM MgCl2 and allowed to proceed for 3 minutes. The reaction 
was stopped with 100% formamide loading dye containing traces of bromophenol blue. Samples were 
resolved on a 12% denaturing polyacrylamide gel followed by phosphorimaging (Amersham Biosciences, 
Piscataway, NJ). For the dose-response experiments, pausing sites caused by inhibition were quantified 
and summed; the % inhibition was calculated as the total amount of inhibited product divided by the 
amount of full-length product plus inhibition products, multiplied by 100. The product fractions were 
normalized and plotted against inhibitor concentration using GraphPad Prism software; the normalized 
data was fitted to a log[inhibitor] versus response curve with variable slope to extract IC50 values for the 
inhibition of the RT enzymes by the -CNP. 
2.4. Site-specific footprinting 
Chemical footprinting with Fe2+ of the template strand was conducted using 50 nM 5'-fluorolabeled DNA 
template (PPT-57) annealed to 150 nM of the primer (PPT+16). The hybrid was incubated with 750 nM 
HIV-1 RT in a buffer containing 120 mM sodium cacodylate (pH 7), 20 mM NaCl, and 6 mM MgCl2 in a 
final volume of 50 μL. Increasing concentrations of G-, T- and A--CNP were added to the samples. 
Samples without inhibitor and without Fe2+ treatment were also included. Pre-incubation of complexes 
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at 37°C for 10 minutes was performed prior to the treatment with Fe2+.  Treatment with Fe2+ was 
performed as previously described (34). 
2.5. Reverse transcriptase assay with homopolymeric template/primers 
The HIV-I RT assays were also carried out in the presence of artificial homopolymeric template/primers. 
Poly(A), dT12-18, dC12-18, poly(I), dA12-18 and poly(C), dG12-18 were from Pharmacia (Uppsala, Sweden). To 
prepare the template/primers for the RT experiments, 0.15 mM poly(C) and poly(A) were mixed with an 
equal volume of 0.0375 mM oligo(dG) and oligo(dT), respectively. The reaction mixture (50 µl) contained 
50 mM Tris.HCl (Sigma, Overijse, Belgium) pH 7.8, 5 mM dithiothreitol (Roche, Vilvoorde, Belgium), 300 
mM glutathione (Sigma), 500 µM EDTA (Sigma), 150 mM KCl (Sigma), 5 mM MgCl2 (Sigma), 1.25 µg of 
bovine serum albumin (Sigma), an appropriate concentration of the tritium-labeled substrate [CH3-
3H]dTTP or [3H]dGTP (2 µCi/assay) (Moravek Biochemicals, Brea, CA), a fixed concentration of the 
template/primer poly(A).oligo(dT) (0.015 mM) or poly(C).oligo(dG) (0.015 mM), 0.06% Triton X-100 
(Sigma), 10 µl of -CNP inhibitor solution (containing various concentrations of the compounds), and 1 µl 
of the HIV-1 RT preparation. The reaction mixtures were incubated at 37°C for 30 minutes, at which time 
100 µl of calf thymus DNA (GE Healthcare, Diegem, Belgium) (150 µg/ml), 2 ml of Na4P207 (Sigma) (0.1 M 
in 1 M HCl), and 2 ml of trichloroacetic acid (Merck, Darmstadt, Germany) (10% v/v) were added. The 
solutions were kept on ice for 30 minutes, after which the acid-insoluble material was washed and 
analyzed for radioactivity. For the experiments in which the 50% inhibitory concentration (IC50) of the 
test compounds was determined, fixed concentrations of 1.25 µM [3H]dTTP or 2.5 µM [3H]dGTP were 
used. In the assays in which the IC50 and Ki values of the test compounds were determined with respect 
to the template/primers, appropriate concentrations of template/primer were used. For the 
experiments in which the Ki values of the test compounds were determined with respect to the 
template/primers, appropriate concentrations of the template/primers were used in the presence of a 
fixed concentration of 2.5 µM [3H]dGTP.  
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2.6. Enzyme assay with HCMV DNA polymerase 
The pGEM3Z-CMV UL54 plasmid for expression of the catalytic subunit (UL54 protein) of HCMV DNA 
polymerase was a generous gift from T. Cihlar (Gilead Sciences, Foster City, CA) (35). Protein expression 
was performed with the TnT® SP6 Quick Coupled Transcription/Translation System (Promega) (36). The 
plasmid was added (at 10 ng per µl volume) to the TnT® mix containing 0.5 mM MgCl2 and 10 mM 
potassium acetate (Janssen Chimica, Beerse, Belgium), and the mixture was incubated for 3 hours at 
30°C. To perform the HCMV DNA polymerase assay, 4 µl of the TnT® reaction product was added to a 46 
µl mixture to obtain 25 mM Tris.HCl pH 8.0, 100 mM (NH4)2SO4 (Sigma), 0.5 mM dithiothreitol, 10 mM 
MgCl2, 0.2 mg/ml bovine serum albumin, 5 % glycerol (Acros, Geel, Belgium), 150 ng per µl activated calf 
thymus DNA (from Amersham Biosciences, Piscataway, N.J.), 100 µM of each of the three unlabeled 
dNTPs (GE Healthcare), and 0.5 µM of the rate-limiting tritium-labeled dNTP, and serial dilutions of the 
-CNP. After 60 minutes incubation at 37°C, nucleic acids were precipitated by addition of 1 ml of ice-
cold 5% TCA and 20 mM Na4P2O7, then spotted onto glass microfiber filters (type G/C; GE Health Care UK 
Limited, Buckinghamshire, UK) and further washed with 5% TCA and ethanol (BDH Prolabs, Dawsonville, 
GA) to remove free radiolabeled dNTP. Radioactivity was determined in a Packard (Perkin Elmer, 
Zaventem, Belgium) Tri-Carb 2300 TR liquid scintillation counter. All radiolabeled materials were 
obtained from Moravek (Brea, CA).  
2.7. Enzyme assay with herpes simplex virus type 1 (HSV-1) DNA polymerase and cellular DNA 
polymerases  and β 
HSV-1 DNA polymerase catalytic subunit (UL30) was expressed in S. frugiperda cells and purified as 
previously described (37). The experiments described here used UL30 fraction V. The reaction mixture 
(40 µl) for the HSV-1 DNA polymerase and cellular DNA polymerase  and β assays contained 4 µl of 
Premix (200 mM Tris.HCl pH 7.5; 2 mM DTT; 30 mM MgCl2), 4 µl of BSA (5 mg/ml), 1.6 µl of activated calf 
thymus DNA (1.0 mg/ml), 0.8 µl of dCTP (5 mM), 0.8 µl of dATP (5 mM), 0.8 µl of dTTP (5 mM), 2 µl of 
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radiolabeled [3H]dGTP (1 mCi/ml) (3.2 µM), 18 µl of H2O, and 4 µl of G--CNP at different serial 
concentrations (i.e., 200, 40, 8, 1.6, 0.32 µM). For testing the T--CNP analogue, 2 µl [3H]dTTP (1 mCi/ml) 
and 0.8 µl unlabelled dCTP, dATP, and dGTP (5 mM) were used. The reaction was started by the addition 
of 4 µl of recombinant HSV-1 DNA polymerase (kindly provided by M.W. Wathen, at that time at Pfizer, 
Kalamazoo, MI or P.E. Boehmer, Phoenix, AZ) or human cellular DNA polymerase  or β (Chimerix, 
Milwaukee, WI) (in 20 mM Tris.HCl pH 8.0; 1 mM DTT; 0.1 mM EDTA; 0.2 M NaCl; 40% glycerol), and the 
reaction mixture was incubated for 60 minutes at 37°C. Then, 1 ml of ice-cold 5% TCA in 0.02 M 
Na4P2O7.10 H2O was added to terminate the polymerization reaction. The consecutive steps (i.e. capture 
of the acid-insoluble precipitate onto filters, filter washing and scintillation counting) were done as 
described above. 
2.8. Kinetic analysis 
The nature of the kinetic interaction of the inhibitors were analysed by the mixed model using a non-
linear regression method available in GraphPad. The mixed model uses a general equation including 
competitive, uncompetitive and noncompetitive inhibition as special cases. The following equations 
were used: Vmax(app) = Vmax/[1+I/αKi]; Km(app) = Km.[1+I/Ki]/[1+I/αKi]; Y = Vmax(app).X/[Km(app)+X], in which X is 
substrate concentration, Y is enzyme activity, Vmax is maximum enzyme velocity, Km = Michaelis-Menten 
constant, I is inhibitor concentration, Ki = inhibition constant, and α is a constant that determines the 
kinetic mechanism. When α = 1, kinetics are noncompetitive. When α is very large, the kinetic model 
approaches a competitive interaction; when α is very small (but greater than zero), the kinetic model 
approaches an uncompetitive interaction.  
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3. Results 
 
3.1. G-α-CNP inhibits HIV and herpes DNA polymerases, but not cellular DNA polymerases 
The inhibitory activity of G-α-CNP was first evaluated against HIV, herpes (i.e. HSV-1, HCMV) and 
cellular DNA polymerases α and β as a racemic mixture of (D)-(-) and (L)-(+). The inhibition by NRTI 
ddGTP, the pyrophosphate analogue PFA, the NNRTI nevirapine, the NcRTI INDOPY-1, and the prototype 
(L)-(-)-thymine-α-CNP were determined in this study for comparison (Table 1). The (±)G-α-CNP analogue 
markedly inhibited HIV-1 RT when poly rC.dG and [3H]dGTP were used as the homopolymeric 
template/primer and dNTP substrate, respectively, but not in the presence of poly rA.dT and [3H]dTTP. 
This homopolymeric template/primer-dNTP selectivity was in agreement with the earlier findings that 
the prototype T-α-CNP was only inhibitory to HIV-1 RT in the presence of its corresponding 
homopolymeric template/primer poly rA.dT-dTTP, but not when any other template/primer-dNTP pair, 
including poly rC.dG and dGTP, were used (21). These data point to a nucleobase (i.e. guanine)-specific 
inhibition of dNTP (i.e. dGTP) incorporation into the corresponding homopolymeric template/primer by 
(±)-G-α-CNP. The (±)G-α-CNP was an equally potent inhibitor of HIV-1 RT as the (±)T-α-CNP derivative 
[IC50: 0.62 µM and 0.41 µM (21), respectively] (Table 1). 
The enantiopure (L)-(+)-G-α-CNP and (D)-(-)-G-α-CNP derivatives have also been synthesized. It 
was observed before that the (D)-enantiomers of the α-CNPs showed poor, if any, inhibitory activity 
against HIV-1 RT (21), and thus, the inhibitory potential of the enantiomeric α-CNP mixtures 
predominantly resided in the (L)-α-CNP enantiomers. A pronounced inhibitory activity of the (L)-(+)-
enantiomer of G-α-CNP was indeed demonstrated  (IC50: 0.41 µM), whereas the (D)-(-)-G-α-CNP 
enantiomer was virtually devoid of anti-HIV-1 RT activity (IC50: 335 µM) (Table 1). The (L)-(+)-G-α-CNP 
derivative was equally inhibitory to HIV-1 RT as 2’,3’-dideoxyguanosine-5’-triphosphate (ddGTP), 
however, at higher efficacy than PFA, nevirapine, and INDOPY-1 in the presence of the poly rC.dG-dGTP 
template/primer-dNTP system. 
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In contrast with HIV-1 RT, inhibition of herpes (i.e. HSV-1, HCMV) DNA polymerases by (±)G-α-
CNP was independent of the nature of the competing dNTP used (Table 1). Thus, (±)-G-α-CNP inhibited 
HSV-1 and HCMV DNA polymerases at the same order of magnitude when either dGTP or dTTP were 
used as the competing radiolabeled substrate (IC50’s ranging between 8 and 32 µM for (±)G-α-CNP and 
between 4.2 and 29 µM for (L)-(+)-G-α-CNP). It was also striking to notice that for the HSV-1 and HCMV 
DNA polymerases the degree of inhibition by the (D)-(-)- and (L)-(+)-G-α-CNP enantiomers did not 
substantially differ. Thus, selective enzyme inhibition by the (D)-(-)-G-α-CNP and/or (L)-(+)-G-α-CNP 
enantiomer strongly depended of the nature of the enzyme: (L)-(+)-G-α-CNP proved highly selective in 
the case of HIV-1 RT, whereas discrimination between (D)-(-)- and (L)-(+)-G-α-CNP was much less striking 
or even non-existing when the herpes HSV-1 and HCMV DNA polymerases were considered. G-α-CNP (as 
also T-α-CNP) showed marginal, if any, relevant inhibition of the cellular DNA polymerases α and β 
pointing to its selectivity for viral DNA polymerases, in particular, herpes DNA polymerases and HIV-1 RT. 
 
3.2. Different kinetic properties of G-α-CNP depending the nature of the DNA polymerase 
The homopolymeric template/primer-dGTP-dependent specificity of G-α-CNP against HIV-1 RT 
strongly suggests competitive inhibition with respect to the incoming corresponding dNTP. Therefore, 
enzyme inhibition kinetics have been investigated for (±)-G-α-CNP. The data were visualized through 
Lineweaver-Burk reciprocal substrate versus velocity plots and analyzed with the mixed model using a 
non-linear regression method available in Graph Pad (Table 2). (±)-G-α-CNP was indeed found to 
competitively inhibit dGTP incorporation into the template/primer poly rC.dG (Fig. 2, panel A) (alpha-
value in the mixed model being 1.799) and was shown to suppress the DNA polymerization by HIV-1 RT 
at a strong trend of non-competitive inhibition with regard to the template/primer (Fig. 2, panel B) 
(alpha-value in the mixed model being 0.147).  
The nature of the kinetic interaction of (±)-G-α-CNP for the herpes DNA polymerases of HSV-1 
and HCMV was clearly different. Instead of competitive inhibition with respect to the dGTP for HIV-1 RT, 
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a most likely mode of noncompetitive kinetics was observed for the HSV-1 and HCMV DNA polymerases 
using calf thymus DNA and [3H]dGTP as the template/primer and radiolabeled dNTP substrate (Fig. 2, 
panels C & D) (alpha-value in the mixed model being 0.386 and 0.905, respectively) (Table 2). Our kinetic 
study findings also imply that (±)G-α-CNP interacts with the substrate-active site of HIV-1 RT, but seems 
to bind to a location different from the substrate-active site in the herpes (i.e. HSV-1, HCMV) DNA 
polymerases. When kinetic experiments have been performed with the enantiopure (L)-(+)-G-α-CNP 
(panels A, B & C) and (D)-(-)-G-α-CNP (panels D & E) derivatives, the different kinetic interactions were 
confirmed between HIV-1 RT (competitive inhibition) on the one hand, and the herpetic DNA 
polymerases, on the other (non-competitive or uncompetitive inhibition) (Fig. 3). In Table 3, the kinetic 
parameters obtained from the non-linear regression analysis by GraphPad for the fitting of the different 
inhibition models are shown. 
 
3.3. The G-α-CNP derivative retards dNTP incorporation and traps the RT in the post-translational state, 
but does not incorporate into the HIV-1 RT-catalyzed growing DNA chain 
HIV-1 RT-catalyzed DNA synthesis was studied in a gel-based assay to gain more insights into the 
mechanism of drug action. A heteropolymeric DNA was used with a well-defined nucleotide sequence. 
All four types of α-CNPs containing either adenine, thymine, cytosine, or guanine nucleobase were 
included for comparison. The experiments showed specific nucleobase-dependent HIV-1 RT inhibition 
patterns. A dose-dependent inhibition of DNA synthesis was observed at a single nucleotide site before 
the predicted location on the template at which the α-CNP would interact (compete) with its 
complementary natural template nucleobase. Thus, the HIV-1 RT-catalyzed nucleotide extension of the 
template/primer complex by dGTP was dose-dependently retarded in the presence of (±)-G-α-CNP but 
not A-, T- or C-α-CNP (most right (fifth) lane series, Fig. 4). Likewise, the α-CNPs containing the other 
nucleobases behaved also selectively depending on the nature of the competing corresponding natural 
nucleotide (second, third, and fourth lane series, Fig. 4). The IC50’s of HIV-1 RT inhibition in the gel-based 
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assay were calculated to be 3.1 ± 2.0, 3.6 ± 1.8, 2.2 ± 0.40 and 1.8 ± 1.1 µM for the A-, T-, C- and G-α-CNP 
derivatives, respectively. Our findings revealed that (±)-G-α-CNP, like the other α-CNPs, are not 
incorporated into the growing DNA chain, which would have changed the primer migration. Time-course 
experiments earlier revealed that the inhibition by the α-CNPs was reversible, whereby the shorter 
reaction products disappeared in function of time, and the full-length end product was eventually 
reached irrespective the nature of the α-CNP nucleobase present in the drug-containing reaction mixture 
(21).  
 The influence of (±)-G-α-CNP on the precise position of HIV-1 RT on the template/primer was 
verified with Fe2+-mediated footprinting. The template is cut in a site-specific manner upon binding of 
the Fe2+ cation to the RNase H domain of HIV-1 RT (24). This specific hydrolysis event enables 
discrimination of the inhibitor interaction in a pre- or post-translocation complex. As shown in Fig. 5, 
increasing concentrations of (±)-G-α-CNP trap the HIV-1 RT enzyme in a post-translocational complex. In 
this respect, G-α-CNP could trap 50% of the complexed enzyme population in the post-translocational 
state at a concentration (0.044 ± 0.002 µM) that was 3- to 20-fold lower than A-α-CNP (0.160 ± 0.034 
µM) and C-α-CNP (1.4 ± 0.49 µM) (Fig. 5). 
 
3.4. Inhibition of HIV-1 RT by G-α-CNP is influenced by amino acid mutations in the vicinity of the active 
site 
The (±)-G-α-CNP analogue has been analyzed for its sensitivity against a wide variety of mutant HIV-1 
RTs, and the fold-resistance values versus wild-type RT were compared with those obtained for the 
corresponding T-, C-, and A-α-CNP analogues as well as for the NcRTI INDOPY-1 (Table 4). Several of the 
mutations in HIV-1 RT have been chosen among those that were reported to play a role in susceptibility 
to INDOPY-1 (14, 25), interact with the cyclopentyl ring of T-α-CNP in the crystal structure (i.e. Y115, 
Q151, and M184) (21), or affect polymerase translocation and fidelity (i.e. F61A, Y115F) (26, 27). The 
most striking degrees of sensitivity loss for (±)-G-α-CNP were displayed by the F61A mutant RT enzymes 
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(79-fold), followed by RTs containing the M184I/V (8.7- to 19-fold) and the V75I (8.7-fold) mutation 
(Table 2). Slight sensitization was observed for the K70E/Q (0.7-fold) mutations, but not for the K70R 
mutation (2.6-fold). Also, the NNRTI-characteristic L100I and Y181C resistance mutations caused a 5.2-
fold resistance, but not the K103N (1.1-fold), V106A (1.6-fold) and E138K (0.9-fold) mutations. The Y115F 
mutation conferred 2.3-fold resistance against (±)-G-α-CNP. Interestingly, when M184V was combined 
with Y115F, the resistance level markedly (synergistically) increased (39-fold). The multidrug resistance-
associated mutation Q151M afforded a 3.1-fold lower sensitivity to (±)-G-α-CNP than the wild-type 
enzyme. 
 When the effects of the HIV-1 RT mutations on the (±)-G-α-CNP’s inhibitory potential were 
compared with their effects on the sensitivities of the mutant enzymes for the corresponding A-, C-, and 
T-α-CNPs, a number of interesting observations could be made: (i) Depending on the nature of the 
nucleobase, the sensitivity level against the mutant enzymes sometimes differed quite substantially. For 
example, the F61A mutation conferred its most pronounced effects on the G and T analogues (79- and 
31-fold, respectively), whereas the A and C analogues were much less affected by this mutation (3.9- and 
5.2-fold, respectively). Also, the M184I/V mutations showed 8.7- to 19-fold, 11- to 12-fold, or 16- to 36-
fold decreased sensitivity for the G-, C- and T-α-CNP analogues, respectively, but only 1.7- to 2.8-fold 
decreased sensitivity for the A-α-CNP analogue. (ii) Whereas a slight sensitization was observed for the 
G-analogue against the mutant K70E/Q enzymes (0.7-fold), such sensitization was more pronounced for 
C-α-CNP (0.2- to 0.3-fold), but was not significantly present for the T-analogue (0.8- to 1.1-fold), whereas 
the A-analogue was rather endowed with a 3- to 3.7-fold decreased inhibitory potential. Sensitization 
was also observed for C-α-CNP against the V106A (0.2-fold) and the Q151M (0.4-fold) mutations and to a 
lesser extent for the A-α-CNP (in both cases 0.8-fold), but absent for the G- and T-analogues (1.1- to 3.1-
fold). (iii) When the inhibition spectrum of C-α-CNP was compared with INDOPY-1, a striking similarity 
could be observed, although the absolute levels of decreased sensitivity/hypersensitivity degree was 
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usually (but not always) less pronounced for INDOPY-1. For example, the sensitization of C-α-CNP 
inhibition against K70E/Q, V106A and Q151M (0.2- to 0.4-fold) was also observed for INDOPY-1 (0.2- to 
0.7-fold), as was also decreased sensitivity to the C-α-CNP (11- to 12-fold) and INDOPY-1 ( 6.7-fold) by 
the mutant M184I/V enzymes. (iv) Whereas the F61A mutation gave consistently the most striking fold-
decrease in sensitivity against all α-CNPs, it hardly affected the inhibitory potential of INDOPY-1 (1.9- to 
2.2-fold). (v) Although the G-, A-, C- and T-α-CNPs show nucleobase-specific inhibitory activity against 
HIV-1 RT irrespective of the nature of the template/primer and competing dNTP (but corresponding to 
the nucleobase present in the α-CNPs), INDOPY-1 showed only inhibitory activity when competing with 
pyrimidine nucleotides (dCTP and dTTP), but not purine nucleotides (dGTP or dATP), as also previously 
reported (14). 
 Taken all data together, it seems that the decreased inhibition of (±)-G-α-CNP is highest for the 
mutant RT enzymes that contain changes in amino acids lining the substrate-binding pocket (i.e. V75I, 
M184I/V) or interact with the template overhang (i.e. F61A). On the other hand, the absolute levels of 
decreased sensitivity (or hypersensitization) can markedly differ depending the nature of the 
nucleobase, pointing to subtle differences in the positioning of the α-CNPs in the substrate-active site of 
HIV-1 RT.  
 
3.5. Modeling of (L)-(+)-G-α-CNP in the substrate-binding site of HIV-1 RT  
The G-α-CNP derivative has been modeled in the substrate-binding site pocket of HIV-1 RT. Analogous 
to T-α-CNP, binding of a G-α-CNP should satisfy the metal chelation, and interactions with a dCMP as the 
first base overhang. We used the crystal structure of the RT/DNA/T-α-CNP ternary complex (21, 23) to 
model an RT/DNA/G-α-CNP complex (Fig. 6), in which the metal chelation geometry, and the 
conformation and interactions of the cyclopentane ring of G-α-CNP were assumed to be very similar to 
those of T-α-CNP. Analogous to the conformation of α-CNP of the RT-bound T-α-CNP, (L)-(+)-G-α-CNP, 
but not (D)-(-)-G-α-CNP, binds favorably at the dNTP-binding site. Residue F61 is located at the base of 
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the β3-β4 fingers loop, and its aromatic side chain is positioned between the first and second template 
overhangs. Additionally, the side chains of F61, I63, and L74 form a hydrophobic cluster, and the cluster 
appears to have impact on dNTP binding, incorporation, and excision via repositioning of the template 
overhang. The L74V mutant RT is less fit for nucleotide incorporation and for excision (28, 29). Molecular 
modeling suggested that L74V might be affecting the positioning of the first template overhang (30). 
The crystal structures of HIV-1 RT/DNA/dATP (or dTTP) were compared to assess differences in 
the mode of binding of a purine vs. pyrimidine nucleobase, but no significant difference was observed 
between the bound states of dATP vs. dTTP. However, the dynamic steps leading to (i) the binding and 
(ii) incorporation of a dNTP, and (iii) translocation after the incorporation might be somewhat dependent 
on specific nucleobase. HIV-1 RTs containing AZT-resistance mutations (or TAM) that efficiently excise 
AZT (3’-azido-ddT) do not effectively excise AZG (3’-azido-ddG) (31), which may suggest subtle 
differences in the preferred positioning of the individual dNTPs and their analogs before and after 
incorporation. We observed significant differences in resistance to A-, T-, G-, and C-α-CNP derivatives by 
mutant F61A RT (Table 4). F61A mutation might affect the positioning of the template overhang, and the 
effect may be different on different types of nucleobases to exhibit and explain the diverse impact on α-
CNP analogs. 
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4. Discussion 
 We recently reported on α-carboxynucleoside phosphonates as a novel class of nucleoside 
phosphonate derivatives that do not need metabolic activation to efficiently interact with the virus-
encoded DNA polymerases (21, 22). Interestingly, crystallographic, biochemical and kinetic studies 
revealed that these compounds bind like N(t)RTIs in the substrate-binding pocket of HIV-1 RT, compete 
with dNTPs that contain the same nucleobase as the α-CNP but, in contrast with NRTIs and NtRTIs, are 
not covalently attached to the primer (21). Whereas these compounds were relatively potent inhibitors 
of HIV reverse transcriptase (IC50’s in the nanomolar range), they proved clearly less inhibitory to herpes 
(i.e. HSV-1, VZV, HCMV) DNA polymerases (IC50’s in the micromolar range) (21).  
We have now synthesized the corresponding guanine derivative, and demonstrated that it had 
comparable inhibitory potencies as the prototype T-α-CNP analogue against HIV-1 RT and the HSV-
1/HCMV DNA polymerases. Interestingly, whereas G-α-CNP was a competitive inhibitor of HIV-1 RT with 
respect to the natural dGTP substrate, G-α-CNP showed non- or uncompetitive inhibition with respect to 
the natural substrate against the HSV-1 and HCMV DNA polymerases. As a result, the lack of competitive 
kinetics against the herpes DNA polymerases are suggestive for an independent mutually non-exclusive 
binding of G-α-CNP and the corresponding natural dNTP to the herpes DNA polymerases, and, therefore, 
G-α-CNP is not expected to interact with the substrate-binding site of the herpes DNA polymerases. Such 
a distinct kinetic nature of enzyme interaction between HIV-1 versus herpes DNA polymerases is unusual 
and unprecedented for a single drug molecule, reflecting molecular and functional diversity between 
different enzymes that have similar enzymatic functionalities. Since the crystallographic complex of HIV-
1 RT with α-CNPs such as T-α-CNP revealed binding of the compound in the substrate-binding pocket of 
HIV-1 RT and G-α-CNP could also be modeled into the HIV-1 RT enzyme’s active site, it would be very 
interesting to obtain crystallographic complexes of the α-CNPs (i.e. G-α-CNP) with the herpes DNA 
polymerase(s) to reveal and define the binding pocket of the α-CNPs in these herpesvirus-encoded 
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enzymes. According to the nature of the observed kinetics, binding to the polymerase dNTP substrate 
active-site domain of the herpes DNA polymerase is rather unlikely. It cannot be excluded that the (D)- 
and (L)-G-α-CNP derivatives are still able to interact with the pyrophosphate binding site of the herpetic 
DNA polymerases in such a manner that independent binding of dNTP to the substrate active site is still 
allowed. However, alternatively, the 3’,5’-exonuclease domain of the herpes enzymes may also be a 
potential candidate site for binding of the α-CNPs. In fact, it has been demonstrated that the antiherpes 
drug acyclovir (as its triphosphate derivative) can bind to the active site of HSV-1 DNA polymerase 
(competitive to dGTP binding) keeping the 3’,5’-exonuclease activity unaffected (32). This means that 
both polymerase and 3’,5’-exonuclease sites can be independently reached by two different drugs in a 
non-mutually exclusive manner. If such binding would effectively occur for G-α-CNP, the 3’,5’-
exonuclease binding pocket should be able to harbor both the (D)-(-)- as well as the (L)-(+)-G-α-CNP 
enantiomer. The identification of the binding pocket of G-α-CNP in the HSV-1 and HCMV DNA 
polymerases may allow rational design and synthesis of novel and selective classes of herpes DNA 
polymerase inhibitors.  
The mechanistically newest class of HIV RT inhibitors are the nucleotide competing RT inhibitors 
(NcRTI) represented by the INDOPY-1 prototype compound (14-16). G-α-CNP closely shares most of the 
kinetic and biochemical properties of the INDOPY derivatives. A number of RT amino acid mutations 
lining the substrate-binding pocket (i.e. M184I/V; Y115F) that partially compromise INDOPY-1 inhibitory 
activity (14), also act as compromising RT mutations for G-α-CNP inhibitory activity. However, other 
mutations such as F61A markedly affect G-α-CNP inhibition, but not INDOPY-1 inhibition. It should, 
however, be noted that the RT sensitivity spectrum of the α-CNPs highly depended on the nature of the 
nucleobase, a property that is also the case for NRTIs when the resistance mutation spectrum of NRTIs 
with different nucleobases (i.e. AZT, ddI, ddC, and carbovir) were compared. Whereas INDOPY’s and α-
CNPs share many kinetic and biochemical similarities with regard to HIV-1 RT inhibition, inhibition of HIV-
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1 RT by INDOPY’s are independent from Mg2+ interactions and are devoid of any anti-herpes DNA 
polymerase activity. Thus, although being NcRTIs, the α-CNPs, in casu G-α-CNP inhibit also herpes DNA 
polymerases, qualifying them as novel inhibitors of multiple viral DNA polymerases.  
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Table 1. Inhibitory activity of G-α-CNP against viral and cellular DNA polymerases 
 IC50
a (µM) 
 HIV-1 RTb  HSV-1 DNA polc  HCMV DNA pold  α DNA pole  β DNA polf 
 poly rC.dG poly rA.dT  calf thymus DNA  calf thymus DNA  calf thymus 
DNA 
 calf thymus 
DNA 
 [3H]dGTP [3H]dTTP  [3H]dGTP [3H]dTTP  [3H]dGTP [3H]dTTP  [3H]dGTP  [3H]dGTP 
(L,D)-(±)G-α-CNP 0.62 ± 0.19 536 ± 0  8 ± 6 32 ± 11  9.4 ± 0.2 16 ± 8  477 ± 83  531 ± 5 
(L)-(+)-G-α-CNP 0.43 ± 0.05 396 ± 48  4.2 ± 0.3 24 ± 15  20 ± 9 29 ± 8  121 ± 75  522 ± 19 
(D)-(-)-G-α-CNP 335 ±54 500  35 ±19 83 ± 29  20 ± 2.4 75 ± 13  >200  195 ± 7 
ddGTP 0.41 ± 0.02 >100  4.5 ± 1.2 >100  48 ± 15 >100  73 ± 8  2.2 ± 1.8 
PFA 17 ± 2 0.55 ± 0.01  1.6 ± 0.8 3.5 ± 1.7  7.0 ± 0.7 9.4 ± 6.0  56 ± 12  >100 
Nevirapine 2.7 ± 0.4 5.6 ± 4.6  >100 >100  >250 >250  >250  >250 
INDOPY >200 0.26 ± 0.07  >100 >100  >100 >100  >100  >100 
(L)-(-)-T-α-CNP >100 0.41 ± 0.10  - 26 ± 20  - 38 ± 11  229 ± 27  >100 
 
a50% inhibitory concentration or compound concentration required to inhibit the polymerase-catalyzed DNA synthesis by 50%. 
bEnzyme reaction in the presence of the homopolymeric poly rC.dG or poly rA.dT, and radiolabeled [3H]dGTP or [3H]dTTP, respectively. 
c-fEnzyme reaction in the presence of calf thymus DNA and radiolabeled [3H]dGTP or [3H]dTTP. 
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Table 2. Kinetic inhibition parameters for (D,L)-(-,+)-G-α-CNP 
Enzyme Parameters Mode of inhibition Most likely mode of 
inhibition 
  Mixed model 
enzyme 
inhibition 
Competitive Non-
competitive 
Uncompetitive  
HIV-1 RT αa 1.799     
(varying dGTP) Ki
b 0.944 0.455 1.30 0.107 (αKi)
e Competitive 
 Km
c 6.02 4.59 6.64 8.97  
 R2d 0.990 0.975 0.989 0.969  
HIV-1 RT αa 0.147     
(varying poly Ki
b 0.832 0.035 0.169 0.1111 (αKi)
e Non-competitive 
rC.dG) Km
c 17.3 15.2 14.6 17.9  
 R2d 0.986 0.915 0.979 0.98  
HSV-1 DNA αa 0.386     
polymerase Ki
b 9.28 0.521 4.17 3.15 (αKi)
e Non-competitive 
(varying dGTP) Km
c 0.101 0.054 0.089 0.1105  
 R2d 0.981 0.854 0.979 0.9787  
HCMV DNA αa 0.904     
polymerase Ki
b 9.20 2.12 8.59 5.455 (αKi)
e Non-competitive 
(varying dGTP) Km
c 0.717 0.561 0.708 0.816  
 R2d 0.986 0.927 0.986 0.975  
 
aThe alpha-value determines the most likely kinetic mechanism: non-competitive inhibition: alpha-value close to 1; competitive inhibition: alpha-value 
much higher than 1; uncompetitive inhibition: alpha-value much lower than 1. 
bKi, inhibition constant. 
cKm, Michaelis-Menten constant. 
dR2 value represents a parameter for the goodness of the curve fit. 
eαKi: inhibition constant being the product of Ki and alpha. 
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Table 3. Kinetic inhibition parameters for (L)-(+)-G-α-CNP and (D)-(-)-G-α-CNP 
Enzyme Inhibitor Parameters Mode of inhibition Most likely mode of 
inhibition 
   Mixed model 
enzyme 
inhibition 
Competitive Non-
competitive 
Uncompetitive  
HIV-1 RT (L)-(+)-G- α-CNPa αb 3.918     
  Ki
c 0.506 0.362 0.850 0.312 (αKi)
f Competitive 
  Km
d 10.5 9.15 13.4 24.1  
  R2e 0.982 0.980 0.979 0.941  
HSV-1 DNA (L)-(+)-G- α-CNPa αb 1.202     
polymerase   Ki
c 2.21 0.362 2.56 1.98 (αKi)
f Non-competitive 
  Km
d 0.084 0.063 0.086 0.094  
  R2e 0.974 0.909 0.974 0.967  
HCMV DNA (L)-(+)-G- α-CNPa αb 0.802     
Polymerase  Ki
c 11.5 2.13 9.81 6.48 (αKi)
f Non-competitive 
  Km
d 0.676 0.559 0.657 0.736  
  R2e 0.980 0.926 0.980 0.973  
HSV-1 DNA (D)-(-)-G- α-CNPa αb 0.002     
Polymerase  Ki
c 7,719 1.97 20.8 15.7 (αKi)
f Uncompetitive 
  Km
d 0.106 0.032 0.077 0.106  
  R2e 0.980 0.777 0.970 0.980  
HCMV DNA (D)-(-)-G- α-CNPa αb 0.213     
Polymerase  Ki
c 122 16.3 42.8 20.5 (αKi)
f Non-competitive 
  Km
d 1.78 1.55 1.51 1.87  
  R2e 0.991 0.946 0.985 0.988  
 
aVarying dGTP. 
bThe alpha-value determines the most likely kinetic mechanism: non-competitive inhibition: alpha-value close to 1; competitive inhibition: alpha-value 
much higher than 1; uncompetitive inhibition: alpha-value much lower than 1. 
cKi, inhibition constant. 
dKm, Michaelis-Menten constant. 
eR2 value represents a parameter for the goodness of the curve fit. 
fαKi: inhibition constant being the product of Ki and alpha. 
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Table 4. Fold-resistance of the α-CNPs against mutant HIV-1 RTs compared to wild-type (control) 
Mutation in 
HIV-1 RT 
G-α-CNP 
Poly rC.dG 
[3H]dGTP 
A-α-CNP 
Poly rU.dA 
[3H]dATP 
C-α-CNP 
Poly I.dC 
[3H]dCTP 
T-α-CNP 
Poly rA.dT 
[3H]dTTP 
INDOPY-1  
Poly rI.dC 
[3H]dCTP 
INDOPY-1  
Poly rA.dT 
[3H]dTTP 
F61A 79 3.9 5.2 31 1.9 2.2 
K65R 2.1 0.8 1.6 1.5 1.3 1.0 
K70E 0.7 3.0 0.2 0.8 0.6 1.5 
K70Q 0.7 3.7 0.3 1.1 0.7 2.5 
K70R 2.6 3.3 2.3 0.9 0.9 0.6 
V75I 8.7 7.0 6.0 2.6 0.9 1.0 
L100I 5.2 3.0 0.5 1.4 2.8 3.9 
K103N 1.1 0.6 1.5 0.6 1.1 0.6 
V106A 1.6 0.8 0.2 1.1 0.4 1.0 
Y115F 2.3 0.8 1.1 2.4 2.9 2.8 
E138K 0.9 0.7 1.5 1.0 1.0 0.7 
Q151M 3.1 0.8 0.4 3.1 0.2 1.6 
Y181C 5.2 1.8 1.5 0.9  6.7 1.3 
M184I 19 2.8 12 36  6.7 5.9 
M184V 8.7 1.7 11 16 > 6.7 7.1 
M184I + E138K 4.2 13 3.5 16 0.6 1.1 
M184V + Y115F 39 5.6 4.1 3.2  6.7 28 
M184V + E138K 6.1 2.6 5.0 3.0 1.0 3.8 
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Figure legends 
 
Fig. 1. Structural formulae of α-CNPs containing different nucleobases. 
 
Fig. 2. Lineweaver-Burk graphic plots for the inhibition of HIV-1 RT (panels A & B), HSV-1 DNA 
polymerase (panel C) and HCMV DNA polymerase (panel D) by (±)-G-α-CNP. In panels A and B, 
homopolymeric rC.dG and [3H]GTP were used as the template/primer and radiolabeled dGTP substrate. 
In panels C and D, calf thymus DNA and [3H]dGTP were used as the template/primer and radiolabeled 
dGTP substrate.  
 
Fig. 3. Lineweaver-Burk plots for the inhibition of HIV-1 RT (panel A), HSV-1 DNA polymerase (panels B 
and D), and HCMV DNA polymerase (panels C and E) by enantiopure (L)-(+)-G-α-CNP and (D)-(-)-G-α-CNP. 
The template/primer and radiolabeled dNTP substrate were similar as those mentioned in the legend to 
Fig. 2, panels A, C, and D. 
 
Fig. 4. Non-incorporative nucleotide-competing inhibition of α-CNPs. 
Inhibition of HIV-1 RT-catalysed DNA synthesis monitored in dose-response experiments in the presence 
of a fixed dNTP concentration, T50A DNA template/5’-radiolabeled P1 DNA primer, and increasing 
concentrations of A-, T-, C- and G-α-CNP, respectively (right block). Specific sites of inhibition by each of 
the four compounds are located a single residue before the inhibitor- and dNTP-binding sites. 
 
Fig. 5. Post-translocation trapping of HIV-1 RT by α-CNPs. 
The precise position of HIV-1 RT on its template/primer was analyzed through Fe2+-mediated 
footprinting. Upon binding of the Fe2+ ion to the RNAse H domain, the template is cut in a site-specific 
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manner that enables the distinction between pre- and post-translocated complexes. Increasing 
concentrations of A-, C-, and G-α-CNP trap the HIV-1 RT as a post-translocated complex. 
 
Fig. 6. RT/DNA/T-α-CNP-based modeling of (L)-(+)-G-α-CNP in the substrate binding-site of HIV-1 RT. 
The template overhang has a cytosine base to allow base pairing with G-α-CNP. The metal ion (B) has 
distorted octahedral coordination involving three oxygens of G-α-CNP and the side chains of catalytic 
aspartates D110 and D185 and main chain carbonyl of V111 (not shown) 
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